Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension

Inclusion Criteria: * Adults aged ≥19 years * Patients diagnosed with stage 1 hypertension according to clinical guidelines * Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice * Patients who are able to undergo ambulatory blood pressure monitoring (ABPM) * Patients who voluntarily agree to participate and provide written informed consent Exclusion Criteria: * Patients with secondary hypertension * Patients with severe hypertension requiring immediate pharmacological i-ntervention * Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs * Patients who are pregnant, planning to become pregnant, or breastfeeding * Patients with severe renal impairment or severe hepatic impairment * Patients who are unable to comply with study procedures, including ABPM * Patients who are deemed inappropriate for participation by the investigator